Acceleron  

Publications

  • Publication
    Dalantercept
    Dec 1, 2016
    A Phase 2 Study of Dalantercept, an Activin Receptor-Like Kinase-1 Ligand Trap, in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancer. December 1, 2016; 122(23):3641-3649
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Nov 6, 2015
    The DART Study Part 1: Updated Results of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium; November 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Nov 6, 2015
    The DART Study Part 2: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium; November 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 15, 2015
    Endothelial ALK1 is a Therapeutic Target for Impairing Metastatic Dissemination of Breast Cancer. Cancer Research June 15, 2015; 75(12):2445-2456
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 1, 2015
    Poster – The DART Study: Dalantercept Part 2. American Society of Clinical Oncology (ASCO) Annual Meeting. June 1, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 1, 2015
    Poster – The DART Study: Dalantercept Part 1. American Society of Clinical Oncology (ASCO) Annual Meeting. June 1, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Feb 28, 2015
    Oral Presentation – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. February 28, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Feb 28, 2015
    Poster – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. February 28, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jan 16, 2015
    The DASH STUDY: A Phase 1b Study of Dalantercept Plus Sorafenib in Advanced Hepatocelluar Carcinoma. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium. January 16, 2015.
    + VIEW FULL Publication
  • Publication
    Dalantercept
    May 30, 2014
    Phase 2 Study of Dalantercept Monotherapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. American Society of Oncology Annual Meeting; May 30 – June 3, 2014
    + VIEW FULL Publication
  • Publication
    Dalantercept
    May 30, 2014
    A Phase 2 Randomized Study of Dalantercept Plus Axitinib Versus Placebo Plus Axitinib in Advanced Renal Cell Carcinoma: Results from the Part 1 Dose Escalation and Expansion Cohorts. American Society of Oncology Annual Meeting; May 30 – June 3, 2014
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Apr 8, 2014
    Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors? Clinical Cancer Research 2014; published online April 8, 2014
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jan 15, 2014
    Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor-like Kinase 1 Ligand Trap, in Patients with Advanced Cancer. Clin Cancer Research 2014;20:482-89
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 30, 2011
    ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011; 117(26): 6999-7006
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Feb 2, 2010
    ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. Mol Cancer Ther 2010; 9(2): 379–88
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jan 1, 2010
    Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010; 207(1): 85-100
    + VIEW FULL Publication